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In 1994, in the UK, histamine-2-receptor antagonists
(H2RAs) were switched from prescription to non-pre-
scription, over-the-counter (OTC) status. However, the
impact of this change has not been studied. 
OBJECTIVE: The objective of this analysis was to evalu-
ate the effects of the change from prescription to OTC on
sales of gastrointestinal products (GIPs). 
METHODS: IMS provided market sales in dollars and
prescription volume for GI products from 1992 to 1997.
All sales figures were converted to 1997 US dollars using
the Consumer Price Index. 
RESULTS: Between 1992 and 1997, total spending on
GIPs increased from $1.09 billion to $1.46 billion. Con-
currently, spending on prescription GIPs rose from $940
million to $1.33 billion with a steady increase in number
of prescriptions for GIPs to 22.2 million by 1997. Since
the introduction of OTC H2RAs in 1994, their market
share amongst all H2RAs has grown modestly from 0.9%
to a high of 1.5% in 1996, when sales were approximately
$7.2 million. The market share of OTC H2RAs amongst
total OTC GIPs reached a high of 0.56% in 1995. 
CONCLUSION: The status change of H2RAs to OTC
status has had a minimal effect on the OTC GIPs sold in
the UK.
PGI4
PRESCRIPTION TO OVER-THE-COUNTER 
PRODUCTS: HISTAMINE-2-RECEPTOR 
ANTAGONISTS IN THE USA
Rolnick M, Furler M, Mak M, Lawday K, Einarson TR
Faculty of Pharmacy, Graduate Department of Pharmaceutical 
Sciences, University of Toronto, Toronto, Ontario, Canada
OBJECTIVE: The purpose of this study was to develop
and refine holistic health state descriptions of diabetic pe-
ripheral neuropathy (DPN) and its complications for a
new utility instrument. 
METHODS: Quality of life domains and health state de-
scriptions related to DPN were developed through a liter-
ature review, previous focus group materials, and expert
opinion. Potential corresponding photographs were iden-
tified by expert opinion. Sixteen veterans with DPN-
related complications were recruited to participate in fo-
cus group discussions of DPN and its impact on quality
of life. Demographic and SF-36 data were also collected.
Semi-structured discussion on the health state descrip-
tions and the quality of life domains were used to refine
and face validate the health state descriptions. A psycho-
metric analysis was performed on eight additional pa-
tients to identify the most appropriate photographs to ac-
company each health state description. 
RESULTS: The mean SF-36 Physical and Mental Com-
ponent Summary scales of the participants were 28.32
and 51.69, respectively. Four broad quality of life do-
mains: symptoms of DPN (numbness, tingling, sensation,
pain, temperature detection), physical function (mobil-
ity), social function (family, leisure activities, social life)
and mental/emotional function (affect, mood, cognition)
were identified. Qualitative exploration of these domains
in four focus group discussions affirmed that these were
the domains of importance to patients. Analysis of the
empiric data from the psychometric experiment unequiv-
ocally demonstrated the photographs to accompany the
health state descriptions. 
CONCLUSIONS: Eight health state descriptions with
photographs were refined and validated by patients.
These health state descriptions will be used with U-Titer,
a customizable utility elicitation software package, to de-
rive preference weights from an at-risk population in
Canada (N  60) and the United Kingdom (N  60).
PGI5
FACTORS INFLUENCING THE DURATION OF GI 
MEDICATION TREATMENT ASSOCIATED WITH 
NSAID-INDUCED GASTROPATHY
Wu WK1, Etzel J1, McHugh J2
1St. John’s University College of Pharmacy, Jamaica, NY, USA; 
2National Medical Health Card Systems, Inc., Port 
Washington, NY, USA
OBJECTIVES: The uses of GI medications for the treat-
ment of and/or prophylaxis of NSAID induced gastropa-
thy can be costly and may not necessarily reduce the risk
of more serious events. The aim of this study was to ex-
amine factors influencing the length of gastrointestinal
(GI) medication usage period associated with concurrent
NSAID use. 
METHODS: This retrospective drug utilization study ex-
amined 15-month pharmacy claims records extracted
from a pharmacy benefit manager’s database. Only pa-
tients (N  454) prescribed an NSAID with no prior GI
medication use were included. This allowed the examina-
tion of those patients’ GI treatment pattern exclusively
attributable to NSAID use. GI medication treatment pe-
riod was evaluated by the Kaplan-Meier method. Factors
affecting the length of treatment period were analyzed us-
ing Cox proportional hazard regression procedure. 
RESULTS: Approximately 30% of the patients received
GI treatment longer than 180 days. The probabilities of a
patient using GI medications longer than 30, 180, and
360 days were 73.40%, 38.77%, and 22.30%, respec-
tively. The mean and median GI medication usage time is
182 and 117 days (CI  90, 147). Cox’s proportional
hazards regression indicated that advanced age (RR 
0.983; CI  0.974, 0.993), long term NSAID therapy
(RR  0.463; CI  0.348, 0.618), earlier introduction of
GI treatment (RR  1.002; CI  1.000, 1.003), and pro-
ton pump inhibitors (PPI) (RR  0.656; CI  0.469,
0.918) were associated with longer GI treatment periods. 
CONCLUSIONS: The results suggest that there is a ten-
dency for patients to receive prolonged course of GI ther-
apy once such treatment was initiated, even though they
were prescribed more potent PPIs. Further outcomes
studies should be pursued to optimize the GI medication
use associated with NSAID induced GI complications.
